Loading…
Chinese maker of peptide (polypeptide) active pharmaceutical ingredients and formulations.
Chinese maker of peptide (polypeptide) active pharmaceutical ingredients and formulations.
Moat: narrow (process know-how). Specialized peptide-synthesis manufacturing know-how versus small-molecule generic makers.
Headquarters: Shenzhen, China · Employees: 1,226
Size Hybio Pharmaceutical (300199.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.08B, the 841st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥24.14 on 6 Nov 2026.
Performance Over six months the shares gained 16.4%, against -3.4% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 70.2% over the last twelve months (peer median +14.8%); the operating margin is 31.4% (peer median 7.4%).
Valuation It trades at 51.4× forward earnings against a peer median of 37.9× (6th most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.1 points above its cost of capital (14.1% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.53B | CN¥963M | CN¥590M | CN¥419M | CN¥688M |
| Revenue growth | — | +63% | +41% | -39% | — |
| Gross profit | CN¥1.03B | CN¥496M | CN¥264M | CN¥131M | CN¥467M |
| EBITDA | n/a | CN¥305M | CN¥110M | -CN¥223M | -CN¥42.2M |
| Net income | CN¥402M | CN¥36.6M | -CN¥174M | -CN¥514M | -CN¥371M |
| Free cash flow | CN¥17.1M | CN¥2.84M | CN¥54.1M | -CN¥85.3M | -CN¥173M |
| Capital expenditure | CN¥327M | CN¥234M | CN¥116M | CN¥81.8M | CN¥190M |
| Total debt | CN¥2.05B | CN¥1.92B | CN¥1.80B | CN¥2.00B | CN¥1.80B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hybio Pharmaceutical 300199.SZ | $3.08B | +16% | +70% | 31% | 51.4× | 40.1% |
| Bachem BANB.SW | $7.32B | +3% | +5% | 19% | 33.1× | n/a |
| PolyPeptide PPGN.SW | $1.62B | +6% | +22% | 7% | 51.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300199.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.6% | +1.7% | 11th highest of 21 |
| 6-month return | +16.4% | -3.4% | 7th highest of 21 |
| Distance from 52-week high | -12.8% | -25.8% | 6th highest of 21 |
| Revenue growth (TTM) | +70.2% | +14.8% | 4th highest of 20 |
| Operating margin | 31.4% | 7.4% | 2nd highest of 20 |
| Forward P/E | 51.4× | 37.9× | 6th most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 40.1% | 25.2% | 5th most demanding of 14 |
| Growth delivered (Del g) | +6.1% | +14.0% | 6th lowest of 14 |
| Hurdle (Req g minus delivered) | +33.9 pp | -9.1 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | +1.1 pp | +0.9 pp | 8th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 51.4× | 40.1% | +6.1% |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | n/a | n/a | n/a |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 44.2× | 25.2% | +14.0% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 21.3× | -2.2% | +7.0% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 16.5× | -7.6% | -9.6% |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 37.9× | 48.9% | +367.3% |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | n/a | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | n/a | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 61.8× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 10.9× | 2.9% | +2.7% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 15.6× | -13.1% | +2.4% |
| China National Medicines 600511.SS | China | $3.31B | +2% | +3% | 4% | 10.7× | -9.8% | +5.4% |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | n/a | 56.9% | +4.2% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 159.9× | n/a | n/a |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | n/a | 31.9% | +159.5% |
| Vericel VCEL | United States | $2.80B | +63% | +23% | 6% | 76.2× | 50.7% | +17.3% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.80B | -43% | +153% | -7% | 100.0× | 42.1% | +22.9% |
| BioArctic BIOA-B.ST | Sweden | $2.78B | -3% | -46% | 22% | 53.4× | 25.7% | +100.1% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% | +61.4% |
| Kangmei Pharmaceutical 600518.SS | China | $2.77B | -22% | -6% | -7% | n/a | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |